Percentage of patients who stopped the initial anti-TNFα therapy after 12, 24 and 36 months
| n | p Value* MTX vs LEF | Months | |||
| 12 | 24 | 36 | |||
| ETA + MTX | 448 | 29.6 | 40.8 | 46.3 | |
| ETA + LEF | 144 | 0.73 | 32.9 | 46.3 | 53.4 |
| ADA + MTX | 566 | 35.1 | 44.3 | 51.3 | |
| ADA + LEF | 174 | 0.074 | 42.5 | 51.5 | 63.1 |
| INF + MTX | 361 | 41.1 | 54.2 | 61.5 | |
| INF + LEF | 76 | 0.31 | 45.7 | 64.6 | 67.1 |
*Comparison of anti-tumour necrosis factor (TNF) agent plus methotrexate (MTX) with anti-TNF agent plus leflunomide (LEF) over 36 months by log rank test. ADA, adalimumab; ETA, etanercept; INF, infliximab.